Lexaria Bioscience (LEXX) FCF Margin (2017 - 2026)

Lexaria Bioscience has disclosed FCF Margin across 10 years of filings, most recently posting 11023.44% for Q1 2026.

• FCF Margin for Q1 2026 came in at 11023.44%, down 1016258.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 2558.49% (down 114206.0% YoY), and the FY2025 annual result was 1483.88%, down 40650.0% from the prior year.
• FCF Margin came in at 11023.44% for Q1 2026 at Lexaria Bioscience, down from 1518.68% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 427.32% in Q1 2024 to a low of 11023.44% in Q1 2026.
• The 5-year median for FCF Margin is 1512.96% (2024), against an average of 2706.3%.
• Across the five-year window, FCF Margin surged 741306 bps in 2022 and plunged 1016258 bps in 2026, its largest moves.
• Lexaria Bioscience's FCF Margin stood at 1295.15% in 2022, then jumped by 40 bps to 781.11% in 2023, then plunged by 91 bps to 1495.57% in 2024, then retreated by 2 bps to 1518.68% in 2025, then sank by 626 bps to 11023.44% in 2026.
• The last three FCF Margin figures came in at 11023.44% (Q1 2026), 1518.68% (Q3 2025), and 2059.74% (Q2 2025), per Business Quant data.